DBV patches up prospects with phase 3 win in infants with peanut allergies

DBV Technologies has chalked up a win for its beleaguered peanut allergy patch candidate, hitting the primary endpoint in a phase 3 clinical trial in infants to send its battered share price past its prior high for 2022.